{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:54:36Z","timestamp":1793904876366,"version":"4.8.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1038\/s41401-020-0478-3","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T04:09:32Z","timestamp":1595390972000},"page":"301-310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":291,"title":["Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma"],"prefix":"10.1038","volume":"42","author":[{"given":"Zhong-jie","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-qi","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-huan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-mei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan-hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-dong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"478_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nrgastro.2012.199","volume":"10","author":"A Villanueva","year":"2012","unstructured":"Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol. 2012;10:34\u201342.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"478_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver.","year":"2018","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182\u2013236.","journal-title":"J Hepatol."},{"key":"478_CR3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"478_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25\u201334.","journal-title":"Lancet Oncol"},{"key":"478_CR5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","volume":"15","author":"JM Llovet","year":"2018","unstructured":"Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599\u2013616.","journal-title":"Nat Rev Clin Oncol"},{"key":"478_CR6","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1634\/theoncologist.2011-0105","volume":"16","author":"T Yau","year":"2011","unstructured":"Yau T, Yao TJ, Chan P, Wong H, Pang R, Fan ST, et al. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist. 2011;16:1270\u20139.","journal-title":"Oncologist."},{"key":"478_CR7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jhep.2019.09.010","volume":"72","author":"S Faivre","year":"2020","unstructured":"Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: looking outside the box. J Hepatol. 2020;72:342\u201352.","journal-title":"J Hepatol."},{"key":"478_CR8","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jhep.2009.03.028","volume":"51","author":"P Newell","year":"2009","unstructured":"Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol. 2009;51:725\u201333.","journal-title":"J Hepatol."},{"key":"478_CR9","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/lt.25191","volume":"24","author":"DH Jung","year":"2018","unstructured":"Jung DH, Tak E, Hwang S, Song GW, Ahn CS, Kim KH, et al. Antitumor effect of sorafenib and mTOR inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence. Liver Transpl. 2018;24:932\u201345.","journal-title":"Liver Transpl."},{"key":"478_CR10","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1158\/1535-7163.MCT-19-0135","volume":"19","author":"CH Lin","year":"2020","unstructured":"Lin CH, Elkholy KH, Wani NA, Li D, Hu P, Barajas JM, et al. Ibrutinib potentiates anti-hepatocarcinogenic efficacy of sorafenib by targeting EGFR in tumor cells and BTK in immune cells in the stroma. Mol Cancer Ther. 2020;19:384\u201396.","journal-title":"Mol Cancer Ther"},{"key":"478_CR11","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1158\/1078-0432.CCR-08-3294","volume":"15","author":"DL Ou","year":"2009","unstructured":"Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, et al. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma. Clin Cancer Res. 2009;15:5820\u20138.","journal-title":"Clin Cancer Res"},{"key":"478_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jhep.2009.10.011","volume":"52","author":"KF Chen","year":"2010","unstructured":"Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, Cheng AL. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J Hepatol. 2010;52:88\u201395.","journal-title":"J Hepatol."},{"key":"478_CR13","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:282\u201396.","journal-title":"Lancet Oncol."},{"key":"478_CR14","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1002\/ijc.25498","volume":"127","author":"G Wei","year":"2010","unstructured":"Wei G, Wang M, Hyslop T, Wang Z, Carr BI. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. Int J Cancer. 2010;127:2949\u201358.","journal-title":"Int J Cancer"},{"key":"478_CR15","doi-asserted-by":"publisher","first-page":"28296","DOI":"10.18632\/oncotarget.5064","volume":"6","author":"HC Pal","year":"2015","unstructured":"Pal HC, Baxter RD, Hunt KM, Agarwal J, Elmets CA, Athar M, et al. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells. Oncotarget. 2015;6:28296\u2013311.","journal-title":"Oncotarget."},{"key":"478_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/cancers12010087","volume":"12","author":"JH Chen","year":"2019","unstructured":"Chen JH, Chiang IT, Hsu FT. Protein kinase B inactivation is associated with magnolol-enhanced therapeutic efficacy of sorafenib in hepatocellular carcinoma in vitro and in vivo. Cancers. 2019;12:87.\u00a0https:\/\/doi.org\/10.3390\/cancers12010087","journal-title":"Cancers"},{"key":"478_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-31209-8","volume":"8","author":"WD Wu","year":"2018","unstructured":"Wu WD, Chen PS, Omar HA, Arafa ES, Pan HW, Jeng J, et al. Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma. Sci Rep. 2018;8:12914.\u00a0https:\/\/doi.org\/10.1038\/s41598-018-31209-8","journal-title":"Sci Rep."},{"key":"478_CR18","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of non-apoptotic cell death. Cell. 2012;149:1060\u201372.","journal-title":"Cell."},{"key":"478_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell BR, Angeli FJP, Bayir H, Bush AI, Conrad M, et al. Ferroptosis: aregulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273\u201385.","journal-title":"Cell."},{"key":"478_CR20","doi-asserted-by":"publisher","first-page":"e02523","DOI":"10.7554\/eLife.02523","volume":"3","author":"SJ Dixon","year":"2014","unstructured":"Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. eLife. 2014;3:e02523.\u00a0https:\/\/doi.org\/10.7554\/eLife.02523","journal-title":"eLife."},{"key":"478_CR21","doi-asserted-by":"publisher","first-page":"517","DOI":"10.18632\/oncoscience.160","volume":"2","author":"N Eling","year":"2015","unstructured":"Eling N, Reuter L, Hazin J, Hamacher-Brady A, Brady NR. Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience. 2015;2:517\u201332.","journal-title":"Oncoscience."},{"key":"478_CR22","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1002\/med.21580","volume":"39","author":"X Sun","year":"2019","unstructured":"Sun X, Yan P, Zou C, Wong YK, Shu Y, Lee YM, et al. Targeting autophagy enhances the anticancer effect of artemisinin and its derivatives. Med Res Rev. 2019;39:2172\u201393.","journal-title":"Med Res Rev"},{"key":"478_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.eng.2018.11.011","volume":"5","author":"J Wang","year":"2018","unstructured":"Wang J, Xu C, Wong YK, Li Y, Liao F, Jiang T, et al. Artemisinin, the magic drug discovered from traditional chinese medicine. Engineering. 2018;5:32\u20139.","journal-title":"Engineering"},{"key":"478_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10111","volume":"6","author":"J Wang","year":"2015","unstructured":"Wang J, Zhang CJ, Chia WN, Loh CCY, Li Z, Lee YM, et al. Haem-activated promiscuous targeting of artemisinin in plasmodium falciparum. Nat Commun. 2015;6:10111.\u00a0https:\/\/doi.org\/10.1038\/ncomms10111","journal-title":"Nat Commun."},{"key":"478_CR25","doi-asserted-by":"publisher","first-page":"33425","DOI":"10.1074\/jbc.M114.564567","volume":"289","author":"ND Yang","year":"2014","unstructured":"Yang ND, Tan SH, Ng S, Shi Y, Zhou J, Tan KSW, et al. Artesunate induces cell death in human cancer cells via enhancing lysosomal function and lysosomal degradation of ferritin. J Biol Chem. 2014;289:33425\u201341.","journal-title":"J Biol Chem"},{"key":"478_CR26","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440\u20136.","journal-title":"Cancer Res."},{"key":"478_CR27","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/cr.2013.11","volume":"23","author":"J Zhou","year":"2013","unstructured":"Zhou J, Tan SH, Nicolas V, Chantal B, Yang ND, Zhang J, et al. Activation of lysosomal function in the course of autophagy via MTORC1 suppression and autophagosome-lysosome fusion. Cell Res. 2013;23:508\u201323.","journal-title":"Cell Res."},{"key":"478_CR28","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671\u20135.","journal-title":"Nat Methods."},{"key":"478_CR29","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/hep.27593","volume":"61","author":"GD Lu","year":"2015","unstructured":"Lu GD, Ang YH, Zhou J, Tamilarasi J, Yan B, Lim YC, et al. CCAAT\/enhancer binding protein \u03b1 predicts poorer prognosis and prevents energy starvation-induced cell death in hepatocellular carcinoma. Hepatology. 2015;61:965\u201378.","journal-title":"Hepatology."},{"key":"478_CR30","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.redox.2016.12.010","volume":"11","author":"JL Roh","year":"2017","unstructured":"Roh JL, Kim EH, Jang H, Shin D. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol. 2017;11:254\u201362.","journal-title":"Redox Biol"},{"key":"478_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/mc.22474","volume":"56","author":"AL Greenshields","year":"2017","unstructured":"Greenshields AL, Shepherd TG, Hoskin DW. Contribution of reactive oxygen species to ovarian cancer cell growth arrest and killing by the anti-malarial drug artesunate. Mol Carcinog. 2017;56:75\u201393.","journal-title":"Mol Carcinog."},{"key":"478_CR32","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.canlet.2008.09.023","volume":"274","author":"I Nakase","year":"2009","unstructured":"Nakase I, Gallis B, Takatani-Nakase T, Oh S, Lacoste E, Singh NP, et al. Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of apoptosis. Cancer Lett. 2009;274:290\u20138.","journal-title":"Cancer Lett."},{"key":"478_CR33","doi-asserted-by":"publisher","first-page":"33046","DOI":"10.18632\/oncotarget.5422","volume":"6","author":"DE Jeong","year":"2015","unstructured":"Jeong DE, Song HJ, Lim S, Lee SJ, Lim JE, Nam DH, et al. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis. Oncotarget. 2015;6:33046\u201364.","journal-title":"Oncotarget."},{"key":"478_CR34","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/MEG.0000000000000066","volume":"26","author":"YP Vandewynckel","year":"2014","unstructured":"Vandewynckel YP, Laukens D, Geerts A, Vanhove C, Descamps B, Colle I, et al. Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial agent. Eur J Gastroenterol Hepatol. 2014;26:861\u201370.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"478_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bbrc.2019.08.115","volume":"519","author":"J Wu","year":"2019","unstructured":"Wu J, Liu S, Xing YR, Zhao RP, Xie J, Hu D, et al. Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma. Biochem Biophys Res Commun. 2019;519:41\u20135.","journal-title":"Biochem Biophys Res Commun"},{"key":"478_CR36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nchembio.2239","volume":"13","author":"S Doll","year":"2017","unstructured":"Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13:91\u20138.","journal-title":"Nat Chem Biol"},{"key":"478_CR37","doi-asserted-by":"publisher","unstructured":"Feng J, Lu PZ, Zhu GZ, Hooi SC, Wu Y, Huang XW, et al. ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma. Acta Pharmacol Sin. 2020. https:\/\/doi.org\/10.1038\/s41401-020-0439-x.","DOI":"10.1038\/s41401-020-0439-x"},{"key":"478_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0526-2","volume":"15","author":"A Houessinon","year":"2016","unstructured":"Houessinon A, Fran\u00e7ois C, Sauzay C, Louandre C, Mongelard G, Godin C, et al. Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib. Mol Cancer. 2016;15:38.\u00a0https:\/\/doi.org\/10.1186\/s12943-016-0526-2","journal-title":"Mol Cancer."}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-0478-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-0478-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-0478-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:03:50Z","timestamp":1684602230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-0478-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["478"],"URL":"https:\/\/doi.org\/10.1038\/s41401-020-0478-3","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,22]]},"assertion":[{"value":"19 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}